Increased perfusion in dynamic gadolinium-enhanced MRI correlates with areas of bone repair and of bone necrosis in patients with Kienbock's disease

Background Osteonecrosis of the lunate, Kienbock's disease, can lead to fragmentation of the lunate, carpal collapse, and severe osteoarthritis. Since the etiology of Kienbock's disease is impaired circulation, a diagnostic method capable of assessing perfusion would be valuable. Recent studies have suggested that dynamic contrast-enhanced (DCE) MR examinations at 3 T can assess perfusion in healthy carpal bones. Purpose To evaluate the use of DCE-MR for assessing perfusion in the lunate bone in patients with Kienbock's disease. Furthermore, to compare perfusion with histopathology with a focus on bone viability. Study Type Prospective case-control study. Population Fourteen patients with Kienbock's disease and a control group of 19 healthy subjects. Field Strength: 3 T with T-1-weighted fat-saturated contrast-enhanced gradient echo series. Assessment Features of the enhancement curves from the DCE-MR examinations, time to peak (TTP), maximum slope (MS), and maximum enhancement (ME) assessed by a radiologist. Six of 14 patients were surgerized with lunate excision, allowing comparison between features of the enhancement curves and histopathology. Statistical Tests Mann-Whitney U-test. P < 0.05 was considered a statistically significant difference. Results Patients with Kienbock's disease showed significantly higher and faster perfusion parameters compared with the control group, the mean value of the TTP in patients was 126.73 sec, in controls 189.79 sec (P = 0.024), ME in patients 173.55 AU, in controls 28.46 AU (P < 0.001), and MS in patients 5.04 AU, in controls 1.06 AU (P < 0.001). When compared with histopathology, increased perfusion was seen in areas of bone formation but also in necrosis. Areas of normal bone showed low perfusion. Data Conclusion DCE-MRI at 3 T can diagnose altered perfusion in patients with Kienbock's disease. Increased perfusion cannot definitely be used as a marker of bone viability. Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2019;50:481-489.